We are pleased to announce that CardioGard, a Peregrine Ventures portfolio company, has received a 510(K) clearance for its Emboli protection cannula, and the device can now be imported into and marketed in the United States. CardioGard is developing a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating from aortic manipulations. The cannula comprises a double lumen where the primary lumen provides oxygenated blood from the heart-lung machine to the patient and a secondary lumen suctions blood and embolic matter away from the surgical field and back to the cardiopulmonary bypass machine for filtrat
We are pleased to announce that CardioGard, a Peregrine Ventures portfolio company, has received a 510(K) clearance for its Emboli protection cannula, and the device can now be imported into and marketed in the United States. CardioGard is developing a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating from aortic manipulations. The cannula comprises a double lumen where the primary lumen provides oxygenated blood from the heart-lung machine to the patient and a secondary lumen suctions blood and embolic matter away from the surgical field and back to the cardiopulmonary bypass machine for filtrat
Otic Pharma Announces Positive Results from a Phase 2 Trial of FoamOtic Externa, once-a-day, single
Otic Pharma Announces Positive Results from a Phase 2 Trial of FoamOtic Externa, once-a-day, single antibiotic, steroid free product for Acute Otitis Externa (AOE) Rehovot, Israel, Jan 6, 2015 – Otic Pharma, a privately held biopharmaceutical company focused on the development of innovative retained, localized foam based products for Ear, Nose and Throat (ENT) disorders, announces positive clinical results of its lead product, FoamOtic Externa. A single agent, steroid free product was studied in a Phase 2 clinical trial with 220 minor and adult patients with Acute Otitis Externa (AOE). Once-daily dosing of FoamOtic Externa (ciprofloxacin 0.3% otic foam) demonstrated excellent safety and a si
Otic Pharma Announces Positive Results from a Phase 2 Trial of FoamOtic Externa, once-a-day, single
Otic Pharma Announces Positive Results from a Phase 2 Trial of FoamOtic Externa, once-a-day, single antibiotic, steroid free product for Acute Otitis Externa (AOE) Rehovot, Israel, Jan 6, 2015 – Otic Pharma, a privately held biopharmaceutical company focused on the development of innovative retained, localized foam based products for Ear, Nose and Throat (ENT) disorders, announces positive clinical results of its lead product, FoamOtic Externa. A single agent, steroid free product was studied in a Phase 2 clinical trial with 220 minor and adult patients with Acute Otitis Externa (AOE). Once-daily dosing of FoamOtic Externa (ciprofloxacin 0.3% otic foam) demonstrated excellent safety and a si
